Qualcomm gives mild forecast, cellphone chip profits fall 17%

Qualcomm gives mild forecast, cellphone chip profits fall 17%


Cristiano Amon, president and CEO of Qualcomm, speaks all through the Milken Institute Global Conference on May possibly 2, 2022, in Beverly Hills, Calif.

Patrick T. Fallon | AFP | Getty Pictures

Qualcomm noted next-quarter earnings on Wednesday that were in line with analyst expectations but noticed profits from handset chips, a core business for the business, decrease 17% on an yearly foundation.

Qualcomm shares fell more than 2% in extended investing.

Here is how the chipmaker did vs . Refinitiv consensus estimates:

  • EPS: $2.15 per share, modified, compared to expectations of $2.15 per share
  • Revenue: $9.27 billion, vs . expectations of $9.1 billion

In the quarter ending in March, Qualcomm explained net profits fell 42% to $1.70 billion, or $1.52 for each share, from $2.93 billion, or $2.57 per share, a calendar year back.

Qualcomm claimed it anticipated all around $8.5 billion in gross sales in the recent quarter, small of Wall Avenue anticipations of $9.14 billion. Analysts were expecting present-day-quarter earnings guidance of $2.16 for every share, but Qualcomm explained it envisioned it that to be around $1.80.

Qualcomm CEO Cristiano Amon in a statement blamed the success on a demanding ecosystem, and the company mentioned it experienced not noticed evidence that smartphone sales are recovering in China. The smartphone industry is on the lookout at a tricky 2023, with shipments for the global market declining in excess of 14% in the very first quarter, according to IDC.

Qualcomm’s chip segment, called QCT, sells smartphone processors, automotive chips, and other components for innovative electronics. It declined 17% to $7.94 billion in income throughout the quarter.

The largest part of QCT’s gross sales come from handset chips, which are the processors at the heart of most Android phones. Qualcomm noted $6.11 billion in handset revenue, down 17% from past 12 months.

Qualcomm’s automotive enterprise, which consists of chips and application for autos, is however modest, whilst it confirmed 20% advancement during the quarter to $447 million in profits. It is really described as aspect of QTL.

Qualcomm’s licensing segment, QTL, which sells obtain to systems desired for mobile assistance, described an 18% once-a-year minimize in revenue to $1.29 billion.

Qualcomm reported it produced $900 million in share repurchases and compensated $800 million in dividends throughout the quarter.



Supply

The case for more Fed rate cuts could rest on a ‘systemic overcount’ of jobs numbers
World

The case for more Fed rate cuts could rest on a ‘systemic overcount’ of jobs numbers

In the Federal Reserve’s battle between fighting inflation and limiting unemployment, the latter side carried the day Wednesday and could also have an edge heading into 2026 if labor market weakness becomes more evident through an apparent overcounting of jobs numbers. In the immediate term, worries over the employment situation meant a vote, albeit divided […]

Read More
Bessent to propose major overhaul of regulatory body created from financial crisis
World

Bessent to propose major overhaul of regulatory body created from financial crisis

U.S. Treasury Secretary Scott Bessent speaks onstage during The New York Times DealBook Summit 2025 at Jazz at Lincoln Center on December 03, 2025 in New York City. David Dee Delgado | Getty Images Entertainment | Getty Images Treasury Secretary Scott Bessent is proposing a major change in the approach to how the government approaches […]

Read More
Eli Lilly’s next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  
World

Eli Lilly’s next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial  

The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly on Thursday said its next-generation obesity drug delivered strong weight loss and reduced knee arthritis pain in a late-stage study, clearing the first of several upcoming trials on the weekly injection.  The […]

Read More